Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2009-03-12
2010-10-19
Coleman, Brenda L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S318000, C514S321000, C514S326000, C546S194000, C546S197000, C546S207000, C546S236000, C546S240000
Reexamination Certificate
active
07816375
ABSTRACT:
One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine, serotonin, or norepinephrine transporters. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, schizophrenia, Parkinson's disease, inflammatory pain, neuropathic pain, Lesche-Nyhane disease, Wilson's disease, and Tourette's syndrome. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds, and the screening of those libraries for biological activity, e.g., in assays based on dopamine transporters.
REFERENCES:
patent: 3806595 (1974-04-01), Jaggers et al.
patent: 3876769 (1975-04-01), Mallion et al.
patent: 3959273 (1976-05-01), Mallion et al.
patent: 4033951 (1977-07-01), Maiser
patent: 4241059 (1980-12-01), Hauck et al.
patent: 4593036 (1986-06-01), Lassen et al.
patent: 4605654 (1986-08-01), Cousse et al.
patent: 5328917 (1994-07-01), Jakobsen et al.
patent: 5521180 (1996-05-01), Fujii et al.
patent: 6110937 (2000-08-01), Loughhead et al.
patent: 6124317 (2000-09-01), Bigge et al.
patent: 6124323 (2000-09-01), Bigge et al.
patent: 6645980 (2003-11-01), Cuny et al.
patent: 6653478 (2003-11-01), Urbanski et al.
patent: 6703383 (2004-03-01), Wu et al.
patent: 6703508 (2004-03-01), Aquila et al.
patent: 2003/0050309 (2003-03-01), Aquila et al.
patent: 2003/0236283 (2003-12-01), Radeke et al.
patent: 2004/0209846 (2004-10-01), Cuny et al.
patent: 0 000 693 (1979-02-01), None
patent: 0 076 089 (1983-04-01), None
patent: 0 080 940 (1983-06-01), None
patent: 0 138 716 (1985-04-01), None
patent: 0 229 623 (1987-07-01), None
patent: 0 266 574 (1988-05-01), None
patent: 0 290 958 (1988-11-01), None
patent: 0 639 568 (1995-02-01), None
patent: 1 221 294 (1960-06-01), None
patent: 2 248 049 (1975-05-01), None
patent: 2 471 378 (1981-06-01), None
patent: 2 534 915 (1984-04-01), None
patent: 2 553 411 (1985-04-01), None
patent: 2 564 462 (1985-11-01), None
patent: 1 138 405 (1969-01-01), None
patent: 1 184 023 (1970-03-01), None
patent: 1 260 886 (1972-01-01), None
patent: 1 382 526 (1975-02-01), None
patent: 1 382 965 (1975-02-01), None
patent: 1 452 701 (1976-10-01), None
patent: 1 501 321 (1978-02-01), None
patent: 111542 (1965-06-01), None
patent: WO 91/09032 (1991-06-01), None
patent: WO 92/01672 (1992-02-01), None
patent: WO 92/02502 (1992-02-01), None
patent: WO 93/15052 (1993-08-01), None
patent: WO 94/13291 (1994-06-01), None
patent: WO 95/03302 (1995-02-01), None
patent: WO 95/25732 (1995-09-01), None
patent: WO 95/33722 (1995-12-01), None
patent: WO 95/33723 (1995-12-01), None
patent: WO 98/51668 (1998-11-01), None
patent: WO 99/65487 (1999-12-01), None
patent: WO 00/09491 (2000-02-01), None
patent: WO 00/71518 (2000-11-01), None
patent: WO 01/32178 (2001-05-01), None
patent: WO 01/68604 (2001-09-01), None
patent: WO 01/92226 (2001-12-01), None
patent: WO 2005/077463 (2005-08-01), None
Andersson et al., 2001, CAS 135:242140.
Balsamo et al., “3-[(2-Ethoxyphenoxy)methyl]piperidine Derivatives. Synthesis and Antidepressant Activity,” Journal of Medicinal Chemistry, 30(1): 222-25 (1987).
Balster et al., “Fixed-Interval Schedule of Cocaine Reinforcement: Effect of Dose and Infusion Duration,” J. Exper. Analysis Behavior, 20: 119-29 (1973).
Brown et al., 1990, CAS 112:35578.
Ding et al., “Pharmacokinetics and In Vivo Specificity of [11C]dl-threo-Methylphenidate for the Presynaptic Dopaminergic Neuron,” Synapse, 18: 152-60 (1994).
Engelstoft and Hansen, “Synthesis and 5-HT Modulating Activity of Stereoisomers of 3-Phenoxymethyl-4-Phenylpiperidines,” Acta Chemica Scandinavica, 50: 164-69 (1996).
Galli et al., “Sodium-Dependent Norepinephrine-Induced Currents in Norepinephrine-Transporter-Transfected HEK-293 Cells Blocked by Cocaine and Antidepressants,” J. Exp. Biol., 198: 2197-212 (1995).
Giros et al., “Cloning, Pharmacological Characterization, and Chromosome Assignment of the Human Dopamine Transporter,” Mol. Pharm., 42: 383-90 (1992).
Gu et al., “Stable Expression of Biogenic Amine Transporters Reveals Differences in Inhibitor Sensitivity, Kinetics, and Ion Dependence,” J. Biol. Chem., 269(10): 7124-30 (1994).
International Search Report Completed on Feb. 27, 2002 and Mailed on Mar. 13, 2002.
International Search Report dated Jun. 29, 2005.
Jones et al., “The Medical Benefit of 5-HT Research,” Pharmacology, Biochemistry and Behavior, 71(4): 555-68 (2002).
Klein et al., “Clinical Efficacy of Methylphenidate in Conduct Disorder with and without Attention Deficit Hyperactivity Disorder,” Arch. Gen. Psychiatry, 54:1073-80 (1997).
Kutsuki et al., 1990, CAS 112:7363.
Madras et al., “Effects of Cocaine and Related Drugs in Nonhuman Primates. I. [3H]Cocaine Binding Sites in Caudate-Putamen,” J. Pharm. Exper. Ther., 251(1): 131-41 (1989).
Nagahara et al., 1994, CAS 120:323168.
O'Neill et al., “Effect of Ca2+and Na+Channel Inhibitors in Vitro and in Global Cerebral Ischaemia in Vivo,” European Journal of Pharmacology, 332: 121-31 (1997).
Parran et al., “Intravenous Methylphenidate Abuse Prototype for Prescription Drug Abuse,” Arch. Intern. Med., 151: 781-83 (1991).
Ritz et al., “Cocaine Receptors on Dopamine Transporters are Related to Self-Administration of Cocaine,” Science, 237: 1219-23 (1987).
Schweri et al., “[3H]Threo-(±)-Methylphenidate Binding to 3,4-Dihydroxyphenylethylamine Uptake Sites in Corpus Striatum: Correlation with the Stimulant Properties of Ritalinic Acid Esters,” J. Neurochem., 45(4) 1062-70 (1985).
Volkow et al., “Dopamine Transporter Occupancies in the Human Brain Induced by Therapeutic Doses of Oral Methylphenidate,” Am. J. Psychiatry, 155(10): 1325-31 (1998).
Volkow et al., “Is Methylphenidate Like Cocaine?”, Arch. Gen. Psychiatry, 52: 456-63 (1995).
Volkow et al., “Methylphenidate and Cocaine Have a Similar In Vivo Potency to Block Dopamine Transporters in the Human Brain,” Life Sciences, 65(1): PL 7-12 (1999).
Notice of Allowability, U.S. Appl. No. 09/951,130, mailed Dec. 1, 2008.
Office Action, U.S. Appl. No. 09/951,130, mailed Jul. 14, 2008.
Office Action, U.S. Appl. No. 09/951,130, mailed Sep. 6, 2007.
Office Action, U.S. Appl. No. 09/951,130, mailed Mar. 1, 2007.
Office Action, U.S. Appl. No. 09/951,130, mailed Jul. 11, 2006.
Office Action, U.S. Appl. No. 09/951,130, mailed Mar. 9, 2006.
Office Action, U.S. Appl. No. 09/951,130, mailed Jul. 13, 2005.
Office Action, U.S. Appl. No. 09/951,130, mailed Dec. 29, 2004.
Office Action, U.S. Appl. No. 09/951,130, mailed May 5, 2004.
Office Action, U.S. Appl. No. 09/951,130, mailed Sep. 24, 2003.
Office Action, U.S. Appl. No. 09/951,130, mailed Jun. 4, 2003.
Office Action, U.S. Appl. No. 09/951,130, mailed Feb. 26, 2003.
Notice of Allowability, U.S. Appl. No. 10/607,457, mailed Mar. 15, 2006.
Office Action, U.S. Appl. No. 10/607,457, mailed Sep. 27, 2005.
Notice of Allowability, U.S. Appl. No. 10/771,519, mailed Jun. 26, 2007.
Office Action, U.S. Appl. No. 10/771,519, mailed Feb. 23, 2007.
Office Action, U.S. Appl. No. 10/771,519, mailed Jul. 24, 2006.
Aquila Brian M.
Bannister Thomas D.
Cuny Gregory D.
Hauske James R.
Holland Joanne M.
Coleman Brenda L
Jones Day
Sepracor Inc.
LandOfFree
Ligands for monoamine receptors and transporters, and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ligands for monoamine receptors and transporters, and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ligands for monoamine receptors and transporters, and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4204659